Finance

Beta
Lists
Equity sectors
Symbols
Symbols
Price
Change
% Change
Trend
Prev Close
Open
High
Low
Volume
Mkt Cap
SIXB
Materials
SIXB
Materials
SIXB
+1.13%
1,053.35
+11.82
+1.13%
—1,041.531,039.461,056.511,038.51——
SIXC
Communications
SIXC
Communications
SIXC
-0.21%
603.99
-1.27
-0.21%
—605.26605.26605.49600.17——
SIXE
Energy
SIXE
Energy
SIXE
-2.53%
1,250.32
-32.42
-2.53%
—1,282.741,281.591,291.361,250.74——
SIXI
Industrials
SIXI
Industrials
SIXI
+1.26%
1,721.65
+21.38
+1.26%
—1,700.271,701.571,728.281,697.55——
SIXM
Financials
SIXM
Financials
SIXM
+1.01%
635.66
+6.35
+1.01%
—629.31629.49636.17625.53——
SIXR
Staples
SIXR
Staples
SIXR
-0.64%
862.26
-5.57
-0.64%
—867.83866.53867.87855.21——
SIXRE
Real estate
SIXRE
Real estate
SIXRE
+0.72%
217.12
+1.55
+0.72%
—215.57215.57217.65215.40——
SIXT
Technology
SIXT
Technology
SIXT
+1.85%
3,552.37
+64.50
+1.85%
—3,487.873,514.713,567.893,502.97——
SIXU
Utilities
SIXU
Utilities
SIXU
+0.35%
898.83
+3.11
+0.35%
—895.72899.33905.79897.93——
SIXV
Health care
SIXV
Health care
SIXV
-0.28%
1,482.33
-4.14
-0.28%
—1,486.471,487.361,493.601,476.64——
SIXY
Discretionary
SIXY
Discretionary
SIXY
+2.19%
2,374.45
+50.88
+2.19%
—2,323.572,327.882,378.252,319.59——
NOVO-B:CPH
Novo Nordisk A/S
DKK 288.40
+0.31%
(+0.90) 1D
May 20, 5:00:00 PM GMT+2  ·   DKK
All symbols
SymbolPriceChange% Change
Generating top insights for NOVO-B...
Open
DKK 282.00
High
DKK 290.65
Low
DKK 282.00
Mkt. cap
974.66B
Avg. vol.
6.12M
Volume
3.60M
52-wk high
DKK 533.40
52-wk low
DKK 224.25
Shares outstanding
3.39B
No. of employees
68K
News stories
From sources across the web
Profile
Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd. Novo Nordisk is controlled by majority shareholder Novo Holdings A/S which holds approximately 28.1% of its shares and a majority of its voting shares. Novo Nordisk manufactures and markets pharmaceutical products and services, specifically diabetes and obesity medications and devices. Novo Nordisk employs more than 48,000 people globally, and markets its products in 168 countries. The corporation was created in 1989, through a merger of two Danish companies, which date back to the 1920s. Novo Nordisk is a full member of the European Federation of Pharmaceutical Industries and Associations. The company was ranked 25th among Fortune's 100 Best Companies to Work For in 2010, and subsequently ranked 72nd in 2014 and 73rd in 2017. In January 2012, Novo Nordisk was named the most sustainable company in the world by the business magazine Corporate Knights, while spin-off company Novozymes was named fourth. It is a leader in the FTSE4Good Index, and the only European company in the top ten. Novo Nordisk is the largest pharmaceutical company in Denmark. Wikipedia
About Novo Nordisk A/S
CEOMaziar Mike Doustdar
Employees67.9K
FoundedDec 21, 1923
HeadquartersBagsværd, Capital Region of Denmark, Denmark
SectorPharmaceutical industry
Websitenovonordisk.com
Previous reportsAll values in DKK
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in DKK
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
76.86B
74.98B
79.14B
96.82B
Cost of goods sold
12.85B
14.47B
14.17B
13.60B
Cost of revenue
12.85B
14.47B
14.17B
13.60B
Research and development expenses
11.69B
11.49B
12.67B
10.28B
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
18.85B
15.76B
17.14B
13.22B
Operating expense
30.56B
27.25B
29.73B
23.61B
Total operating expenses
43.41B
41.72B
43.90B
37.20B
Operating income
33.45B
33.25B
35.24B
59.62B
Other non operating income
-
1.53B
-241.00M
-
EBT including unusual items
33.80B
25.52B
34.18B
62.17B
EBT excluding unusual items
33.80B
35.09B
37.62B
62.17B
Income tax expense
7.30B
5.51B
7.29B
13.62B
Effective tax rate
21.60%
21.60%
21.34%
21.90%
Other operating expenses
23.00M
-
-81.00M
106.00M
Net income
26.50B
20.01B
26.89B
48.56B
Net profit margin
34.48%
26.68%
33.98%
50.15%
Earnings per share
5.96
4.50
6.04
6.63
Interest and investment income
5.31B
307.00M
4.41B
-
Interest expense
-4.96B
-
-4.97B
-
Net interest expenses
356.00M
307.00M
-560.00M
-
Depreciation and amortization charges
-
-
-
-
EBITDA
37.65B
36.49B
36.66B
63.13B
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

My tasks
You haven't created a task yet
Your tasks will appear here. Schedule tasks and put Google Finance to work while you're away.
Templates
Watchlist briefing
A daily pre-market analysis of your watchlist
Upcoming Earnings
Upcoming earnings reports in the week
Abnormal Volatility & Volume
Volatility and volume early warning today
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer